新辅助化疗联合免疫治疗后腹腔镜胃癌手术的疗效与安全性分析OACSTPCD

Objective:To investigate the clinical efficacy and safety of laparoscopic gastric cancer surgery after neoadjuvant chemotherapy combined with immunotherapy.Methods:Clinical data of 113 patients with advanced gastric cancer who underwent lapa-roscopic gastric cancer surgery after neoadjuvant chemotherapy were retrospectively analyzed.All patients were divided into neoadjuvant chemotherapy combined with immunotherapy group(combined group,n=37)and neoadjuvant chemotherapy(neoadjuvant group,n= 76).And the prognosis and clinical data of the two groups were compared.Results:The baseline characteristics between the two groups were comparable.Compared with neoadjuvant group,the combined group has longer overall survival time(P=0.002)and disease-free survival time(P<0.001).In terms of clinical efficacy,the combined group was significantly lower than the neoadjuvant group in tumor regression grade(P<0.001),T stage(P=0.022)and N stage(P=0.008),and the combined group was less in number of vascular invasion(P=0.007),postoperative recurrence(P=0.017)and postoperative metastasis(P=0.033).No significant difference in the intraoperative blood transfusion,postoperative hospital stay,fever time,exhaust time,complications incidence,and rate of adverse reac-tions(neutropenia,lymphopenia and thrombocytopenia)were found between the two groups.Conclusions:Laparoscopic gastric cancer surgery after neoadjuvant chemotherapy combined with immunotherapy is safe and feasible,and can effectively improve the prognosis of advanced gastric cancer patients.